Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 StudyLuis Paz‐Ares, C. Chouaïd, Nicolas Girard et al.|Journal of Clinical Oncology|2024Cited by 126
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trialArlene O. Siefker‐Radtke, Wei Xue, Nobuaki Matsubara et al.|Annals of Oncology|2023Cited by 82
A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trialGilberto de Castro, Nils Gunnar Skare, J. G. M. Segalla et al.|European Journal of Cancer|2017Cited by 57